Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Renalytix Plc (LSE:RENX) has formed a strategic partnership with New York Kidney & Hypertension Medicine (NYKHM) aimed at increasing access to its FDA-approved kidneyintelX.dkd test in underserved areas of the Greater New York region. This initiative is set to benefit over 2,000 patients, enabling earlier and more personalized risk assessment for chronic kidney disease (CKD).
The collaboration is not only focused on delivering diagnostics but also includes educational outreach to local healthcare providers and awareness campaigns for patients. These efforts are intended to drive early detection, improve disease management, and ultimately enhance outcomes and quality of life for those at risk of progressive kidney damage.
Despite operational challenges—such as ongoing financial strain, revenue contraction, and high losses—Renalytix continues to pursue growth through strategic alliances like this one. Although the stock’s technical and valuation indicators remain under pressure, partnerships that expand access and visibility could signal longer-term potential.
About Renalytix
Renalytix is a diagnostics company leveraging artificial intelligence to transform kidney disease management. Its lead product, kidneyintelX.dkd, is the first and only prognostic test of its kind approved by the FDA and covered by Medicare. Designed for patients with type 2 diabetes and early to moderate stages of CKD, the test supports clinicians with data-driven risk assessment to personalize treatment strategies. Renalytix operates primarily in the United States, collaborating with health systems and physician groups to advance the standard of care in kidney health.
